Physician profile
Robert J Strickmeyer
NPI 1184621179
$10,015.60
in general payments reported to CMS, 2019-2025
32 companies · $1,333 in 2025
The $1,333 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,178 · 2020: $1,136 · 2021: $1,824 · 2022: $1,329 · 2023: $1,411 · 2024: $1,805 · 2025: $1,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,548.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,514.47 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,503.82 | 2019-2024 | Xarelto |
| Amgen INC. | $1,188.30 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $931.41 | 2019-2025 | Watchman Access System |
| Astrazeneca Pharmaceuticals Lp | $676.50 | 2019-2025 | Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $581.72 | 2019-2025 | Jardiance |
| Pfizer INC. | $535.55 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $493.15 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $448.68 | 2019-2022 | |
| Medtronic, INC. | $271.85 | 2024 | Corevalve Evolut R, Ffrangio |
| Esperion Therapeutics, INC. | $271.27 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $241.77 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $226.49 | 2022-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $204.07 | 2019-2024 | |
| Abbott Laboratories | $173.59 | 2021-2023 | Mitraclip |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $96.61 | 2021-2025 | Impella |
| Regeneron Healthcare Solutions, INC. | $80.85 | 2019-2023 | Evkeeza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.00 | 2019-2020 | |
| Irhythm Technologies, INC. | $73.77 | 2020-2023 | Zio Xt Patch |
| Kowa Pharmaceuticals America, INC. | $58.15 | 2019-2021 | |
| Scpharmaceuticals INC. | $51.77 | 2024-2025 | |
| Lundbeck LLC | $51.11 | 2019-2020 | |
| Novo Nordisk INC | $50.14 | 2019-2023 | Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $47.70 | 2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Biosense Webster, INC. | $33.93 | 2021 | |
| Lilly USA, LLC | $31.79 | 2025 | Mounjaro, Zepbound |
| Kestra Medical Technology Services, INC. | $21.14 | 2024 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $19.43 | 2019 | |
| Glaxosmithkline, LLC. | $19.11 | 2025 | Shingrix, Arexvy |
| Lexicon Pharmaceuticals, INC. | $17.45 | 2023 | Inpefa |
| Chiesi USA, INC. | $14.41 | 2021 | |
| Astellas Pharma US INC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Strickmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.